3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
221
Polycystic Ovary Syndrome
36
Endometrial Neoplasms
15
Ovarian Neoplasms
13
Infertility
11
Neoplasm Metastasis
9
Carcinoma, Intraductal, Noninfiltrating
7
Fallopian Tube Neoplasms
6
Neoplasms
5
Breast Diseases
5
Triple Negative Breast Neoplasms
4
Osteoporosis
4
Leiomyoma
4
Infertility, Female
4
Breast Neoplasms, Male
4
Breast Carcinoma In Situ
4
Arthralgia
4
Advanced Breast Cancer
4
Recurrence
3
Obesity
3
Breast Cancer Metastatic
3
Anovulation
3
Uterine Neoplasms
2
Solid Tumor
2
Prostatic Neoplasms
2
Progesterone Resistance
2
Pancreatic Neoplasms
2
Pain
2
Leiomyosarcoma
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Interventions
Cyclophosphamide
23
Paclitaxel
19
Epirubicin
14
Doxorubicin
13
Carboplatin
13
Trastuzumab
12
Docetaxel
10
Taxes
9
Albumin-Bound Paclitaxel
7
pembrolizumab
5
Radiotherapy
5
Fluorouracil
5
Filgrastim
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
pertuzumab
4
Neoadjuvant Therapy
4
Cisplatin
4
eribulin
3
Thiotepa
3
Tamoxifen
3
Panitumumab
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Flow Cytometry
3
Capecitabine
3
Biopsy
3
sargramostim
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Inflammatory Breast Neoplasms
×
Letrozole
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled